Mark Raza Principal Deputy Chief Counsel - FDA | Official Website
Mark Raza Principal Deputy Chief Counsel - FDA | Official Website
This is a 55.6% increase over the number of companies cited in the previous year.
Of the 71 citations issued, the most common citations include:
- Procedures to ensure that all purchased or otherwise received product and services conform to specified requirements have not been adequately established.
- Procedures for corrective and preventive action have not been adequately established.
- Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been adequately established.
Most of the companies cited were involved in the Devices sector. The second most common type of company cited in the time period worked in the either Food and Cosmetics or Drugs sectors.
Of the companies cited, 13 should take voluntary actions to correct their managing operations (92.9%). Additionally, one company had to take regulatory and/or administrative actions (7.1%).
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
Company Name | Area of Business | Inspection Date | Issue Cited |
---|---|---|---|
BL Bio Lab | Food and Cosmetics | 06/30/2023 | Quality control - required operations product complaints |
BL Bio Lab | Food and Cosmetics | 06/30/2023 | Manufacturing operations - written procedures |
BL Bio Lab | Food and Cosmetics | 06/30/2023 | Metal, foreign material |
Body, LLC | Food and Cosmetics | 05/18/2023 | Records - equipment; calibrations, inspections, checks |
Body, LLC | Food and Cosmetics | 05/18/2023 | Documentation - quality control, review, approve supplier |
Body, LLC | Food and Cosmetics | 05/18/2023 | Batch record - complete |
Body, LLC | Food and Cosmetics | 05/18/2023 | Batch record - identifier; labels |
Catalent Pharma Solutions, LLC | Food and Cosmetics | 07/21/2023 | Equipment - maintain, clean, sanitize |
Catalent Pharma Solutions, LLC | Food and Cosmetics | 07/21/2023 | Specifications - component identity |
Catalent Pharma Solutions, LLC | Food and Cosmetics | 07/21/2023 | Specifications-component purity, strength, composition |
Catalent Pharma Solutions, LLC | Food and Cosmetics | 07/21/2023 | Specifications - contamination limits |
Catalent Pharma Solutions, LLC | Food and Cosmetics | 07/21/2023 | Specifications - labels, packaging |
Catalent Pharma Solutions, LLC | Food and Cosmetics | 07/21/2023 | Specifications - identity, purity, strength, composition |
Catalent Pharma Solutions, LLC | Food and Cosmetics | 07/21/2023 | Master manufacturing record - unique formulation |
Catalent Pharma Solutions, LLC | Food and Cosmetics | 07/21/2023 | Batch record - complete |
Eagle Labs, Inc. | Drugs | 12/06/2023 | Written procedures not established/followed |
Eagle Labs, Inc. | Drugs | 12/06/2023 | SOPs not followed / documented |
Florida Fertility Institute, P. A. | Biologics | 02/02/2023 | Procedures for all other requirements |
Florida Fertility Institute, P. A. | Biologics | 02/02/2023 | Testing, screening, donor eligibility procedures |
Florida Fertility Institute, P. A. | Biologics | 02/02/2023 | Determination based on screening and testing |
Florida Fertility Institute, P. A. | Biologics | 02/02/2023 | Responsible person to determine, document |
Florida Fertility Institute, P. A. | Biologics | 02/02/2023 | Name and personal info on accompanying records |
Florida Fertility Institute, P. A. | Biologics | 02/02/2023 | Labeled re: biohazard, risks, test results |
Florida Fertility Institute, P. A. | Biologics | 02/02/2023 | Risk factors, clinical evidence |
Florida Fertility Institute, P. A. | Biologics | 02/02/2023 | Eligibility not required--warning labels |
Infinium Medical, Inc. | Devices | 11/08/2023 | Individual Report of Malfunction |
Infinium Medical, Inc. | Devices | 11/08/2023 | Service reports/MDRs/complaints |
J&T Health and Wellness, LLC | Devices | 10/18/2023 | Design Validation - Risk analysis not performed/inadequate |
J&T Health and Wellness, LLC | Devices | 10/18/2023 | Design changes - Lack of or Inadequate Procedures |
J&T Health and Wellness, LLC | Devices | 10/18/2023 | Documentation of software validation |
J&T Health and Wellness, LLC | Devices | 10/18/2023 | Calibration, Inspection, etc. Procedures Lack of or Inadequ |
J&T Health and Wellness, LLC | Devices | 10/18/2023 | Documentation |
J&T Health and Wellness, LLC | Devices | 10/18/2023 | Nonconforming product, Lack of or inadequate procedures |
J&T Health and Wellness, LLC | Devices | 10/18/2023 | Lack of or inadequate procedures |
J&T Health and Wellness, LLC | Devices | 10/18/2023 | Lack of or inadequate complaint procedures |
Jennifer W. Leiding, M.D. | Biologics | 09/08/2023 | Informed consent |
Jennifer W. Leiding, M.D. | Biologics | 09/08/2023 | Case history records- inadequate or inadequate |
Jennifer W. Leiding, M.D. | Biologics | 09/08/2023 | Safety Reports - Non-Serious Events |
McPherson Enterprises, Inc. | Devices | 09/06/2023 | Design Validation - Risk analysis not performed/inadequate |
McPherson Enterprises, Inc. | Devices | 09/06/2023 | Design validation acceptance criteria |
McPherson Enterprises, Inc. | Devices | 09/06/2023 | Purchasing controls, Lack of or inadequate procedures |
McPherson Enterprises, Inc. | Devices | 09/06/2023 | Environmental control Lack of or inadequate procedures |
Pharmetric Laboratory, LLC | Drugs | 11/06/2023 | Procedures not in writing, fully followed |
Regenerative Processing Plant, LLC | Drugs | 06/30/2023 | Procedures not in writing, fully followed |
Regenerative Processing Plant, LLC | Drugs | 06/30/2023 | Buildings of Suitable Size, Construction, Location |
Regenerative Processing Plant, LLC | Drugs | 06/30/2023 | Environmental Monitoring System |
Regenerative Processing Plant, LLC | Drugs | 06/30/2023 | Cleaning / Sanitizing / Maintenance |
Regenerative Processing Plant, LLC | Drugs | 06/30/2023 | Written procedures not established/followed |
Regenerative Processing Plant, LLC | Drugs | 06/30/2023 | Component identification test |
Regenerative Processing Plant, LLC | Drugs | 06/30/2023 | Protection from external factors |
Regenerative Processing Plant, LLC | Drugs | 06/30/2023 | Validation lacking for sterile drug products |
Regenerative Processing Plant, LLC | Drugs | 06/30/2023 | Samples (various types) representative, identified properly |
Regenerative Processing Plant, LLC | Drugs | 06/30/2023 | Results not used for expiration dates, storage cond. |
Regenerative Processing Plant, LLC | Drugs | 06/30/2023 | Retention time of reserve samples, in general |
Regenerative Processing Plant, LLC | Drugs | 06/30/2023 | Record maintenance 1 year (except exempt OTC) |
Regenerative Processing Plant, LLC | Drugs | 06/30/2023 | Identification of each component or in-process material |
Regenerative Processing Plant, LLC | Drugs | 06/30/2023 | Investigations of discrepancies, failures |
Regenerative Processing Plant, LLC | Drugs | 06/30/2023 | Complete Test Data |
Sun Dental Laboratories, LLC | Devices | 09/20/2023 | Lack of Written MDR Procedures |
Sun Dental Laboratories, LLC | Devices | 09/20/2023 | Supplier notification of changes |
Sun Dental Laboratories, LLC | Devices | 09/20/2023 | Labeling inspection - UDI |
Suncoast Dental, Inc. | Devices | 05/04/2023 | Design verification - output does not meet input requirement |
Suncoast Dental, Inc. | Devices | 05/04/2023 | Design Validation - Risk analysis not performed/inadequate |
Suncoast Dental, Inc. | Devices | 05/04/2023 | Lack of or inadequate procedures - Acceptance activities |
Suncoast Dental, Inc. | Devices | 05/04/2023 | Documentation |
Ultra Clean Systems, Inc. | Devices | 08/11/2023 | Lack of System for Timely Submission of Reports |
Ultra Clean Systems, Inc. | Devices | 08/11/2023 | Design control - no procedures |
Ultra Clean Systems, Inc. | Devices | 08/11/2023 | Purchasing controls, Lack of or inadequate procedures |
Ultra Clean Systems, Inc. | Devices | 08/11/2023 | Software validation for automated processes |
Ultra Clean Systems, Inc. | Devices | 08/11/2023 | Lack of or inadequate procedures |
Ultra Clean Systems, Inc. | Devices | 08/11/2023 | Lack of or inadequate complaint procedures |